NGENF News and Press, NervGen Pharma Corp

New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...

Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway...

Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQ...

Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged...

2024-04-17 11:54:32 ET NervGen Pharma press release ( OTCQX:NGENF ): FY GAAP EPS of -$0.38. NervGen had cash and investments of $11.7 million as of December 31, 2023, compared to $22.5 million as of December 31, 2022. Read the full article on Seeking Alpha For fu...

Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NV...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (" NervGen " or the " Company ") is pleased to announce the closing of its previously ann...

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 20...